Our findings supported this concept, providing important mechanistic insights relevant to cytokine-based drug design and showcasing the previously underestimated potential of CD25-biased IL-2cx and ICs in cancer immunotherapy, particularly in combination with ICIs. Here, IL2RA is linked to cancer.